NASDAQ | DRNA

$9.54 + 0.06 (+0.633%)

3 month stock price graph

4:00 PM ET on Nov 17, 2017 Pricing delayed 20 minutes

Investors & Media

Press Releases

 
Press Releases
  Date Title and Summary View
Nov 8, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Stifel 2017 Healthcare Conference ...
Nov 2, 2017
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the third qua...
Nov 2, 2017
INGELHEIM, Germany and CAMBRIDGE, Mass., U.S.A., November 2, 2017 – Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced a research collaboration and license agreement to discover and develop novel GalXC™ RNAi therapeutics for the trea...
Oct 26, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2017 financial results after market close on Thursday, November 2, 2017. ...
Oct 16, 2017
The Company Expects to Initiate Clinical Dosing in Q1 2018 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the first submission of a clinical trial applicat...
Sep 20, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in an analyst-led fireside chat at ...
Sep 5, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Rodman & Renshaw 19th Ann...
Aug 10, 2017
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the second qu...
Aug 3, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2017 financial results after market close on Thursday, August 10, 2017. ...
Jul 17, 2017
DCR-PHXC Achieved Broad, Durable, and Consistent Knockdown of LDHA and Reduction of Oxalate in Multiple Animal Models of PH New Data Presented at 12th International PH Workshop Also Include Update from PHYOS Trial of Patients with PH1 Management to Host Conference Call Today at 10:...
Page:
1
... NextLast
= add release to Briefcase